Key & Strategic Account Manager
About the job
- A bachelor's degree or higher in Life Sciences, Molecular Biology, Biotechnology, or a related field is required.
- Over 5 years of account management, sales, or strategic planning experience in life sciences or biotech sectors is required.
- A customer-centric mindset with strong relationship-building and influencing skills is required.
- Solid scientific and technical knowledge, with the ability to communicate complex concepts effectively, is required.
- Teamwork and leadership capabilities across cross-functional teams are required.
- Data-driven analytical skills and strategic thinking are required.
- Motivation to meet and exceed targets is required.
- Develop and execute tailored sales strategies and business plans for assigned key and strategic accounts.
- Establish and maintain trusted relationships with key customers and executive decision-makers.
- Engage proactively with new and existing customers through face-to-face meetings, phone, email, and digital channels to drive sales growth.
- Deliver technical and scientific presentations and provide consulting on Bio-Techne products and solutions.
- Collaborate with sales, marketing, and technical support teams to develop customized solutions and coordinate joint events.
- Analyze customer and market data to identify priority accounts and focus sales efforts effectively.
- Identify new business opportunities through cross-selling and upselling.
- Represent Bio-Techne at industry events and conferences to build a network and enhance brand presence.
- Forecast and report account revenue and sales performance.
- Monitor market trends and competitor activities to support strategic decision-making.
- A master's degree or MBA is preferred.
- Experience negotiating and presenting to senior executives is a plus.
About the company
Bio-Techne makes and sells life-science tools such as purified proteins, cytokines, growth factors, antibodies, immunoassays, and reagent solutions, along with ProteinSimple analytics and cell/gene therapy workflow technologies. Researchers use these products to produce, analyze, and quantify biomolecules and to carry out assays and workflow steps in cancer, immunology, and regenerative medicine. The company differentiates itself with a broad, integrated catalog and end-to-end support—from raw proteins to analytical solutions—delivered to a global customer base. Its goal is to be a leading provider of life-science tools that speed up discovery and development in healthcare and biology.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Minneapolis, Minnesota
Founded
1981
Get referred to Bio-Techne
See people who can refer or advise you
Simplify's Take
What believers are saying
- Bio-Techne shareholders approved Merck’s acquisition on September 23, 2026, clearing a major hurdle.
- August 12, 2026 results showed 3% organic fourth-quarter growth and 310-basis-point margin expansion.
- July 2026 AI-engineered proteins expand cell-therapy demand and strengthen advanced culture workflows.
What critics are saying
- Merck’s $73-per-share acquisition closes late 2026 or early 2027, ending independence.
- Fiscal 2026 revenue stayed flat at $1.2 billion, exposing weak organic demand.
- Restructuring through fiscal 2027 and Merck integration threaten roles, autonomy, and duplicated functions.
What makes Bio-Techne unique
- Bio-Techne’s 50-year protein catalog still anchors customer loyalty across research workflows.
- ProteinSimple, RNAscope, and spatial biology create sticky, integrated tools across discovery.
- The Düsseldorf Customer Experience Center deepens European adoption of Bio-Techne workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Short-term Disability
Long-term Disability
Pet Insurance
Legal Services
401(k) Company Match
Company Equity
Professional Development Budget
Paid Vacation
Paid Sick Leave
Paid Holidays
Parental Leave
Unlimited Paid Time Off
Hybrid Work Options
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
2%1 year growth
2%2 year growth
2%Bio-Techne expands global GMP manufacturing network with new Bristol facility to advance scalable cell therapy development. Bio-Techne Corporation, a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges: establishing scalable, reproducible manufacturing processes that can support programs from early development through commercialization. A guide to advancing biotherapeutic research eBook. Welcome to your essential guide to advancing biotherapeutic research. The purpose-built 10,000-square-foot Bristol facility features five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling. Designed to meet the rigorous standards required for advanced cell therapy manufacturing, the facility enhances Bio-Techne's ability to provide customers with high-quality GMP materials supported by robust quality systems and reliable global supply. "As the cell therapy field continues to mature, success increasingly depends on the ability to manufacture therapies consistently and at scale," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our investment in Bristol demonstrates Bio-Techne's commitment to providing customers with the GMP materials, manufacturing expertise, and supply chain reliability needed to accelerate development and ultimately bring transformative therapies to patients worldwide." The Bristol expansion is the latest milestone in Bio-Techne's broader strategy to build a comprehensive manufacturing network supporting every stage of the cell therapy workflow. Together with the company's recombinant protein manufacturing operations in Minneapolis, Minnesota, its extensive GMP capabilities in St Paul, and its strategic relationship with Wilson Wolf Corporation, a leading manufacturer of cell culture devices including the widely adopted G-Rex(R) platform, Bio-Techne offers an increasingly integrated portfolio of GMP proteins, GMP small molecules, GMP cell media, custom manufacturing services, analytical solutions, and process development support. Collectively, these capabilities help customers transition seamlessly from research through clinical development and commercial production. Cell therapy developers face mounting pressure to reduce variability, standardize manufacturing processes, and scale production efficiently while meeting evolving regulatory expectations. Bio-Techne addresses these challenges through high-quality GMP materials, scalable manufacturing solutions, and analytical technologies designed to improve consistency and accelerate development timelines. Recent industry discussions have increasingly highlighted manufacturing scalability as a critical factor in enabling broader patient access to advanced therapies, reinforcing the importance of investments such as the Bristol expansion. The opening of its Bristol facility represents more than additional manufacturing capacity. It strengthens Bio-Techne's ability to serve as a long-term partner for cell therapy innovators by providing the quality, scale, and global support necessary to navigate the journey from discovery to commercial supply." Will Geist, President of Bio-Techne's Protein Sciences Segment The Bristol facility is fully operational and is manufacturing GMP-grade small molecules that support customers developing next-generation cell therapies worldwide. Be the first to rate this article
Bio-Techne opens gmp-grade small-molecule manufacturing facility in Bristol, UK. The site further expands Bio-Techne's global capabilities in supporting a burgeoning cell therapy market. October 8, 2026 Content Marketing Editor Editor's Take: Combining with Bio-Techne's capabilities in Minnesota, this comes amid a pending acquisition by Merck KGaA, Darmstadt, Germany. Bio-Techne opened a new manufacturing facility in Bristol, United Kingdom, for good manufacturing practice (GMP)-grade small molecules. The site further expands Bio-Techne's global capabilities in terms of supporting the growing cell therapy market. As a provider of life science tools, reagents, and diagnostic products, Bio-Techne helps therapy developers address pressing industry challenges. One of the foremost of these is establishing scalable and reproducible manufacturing processes to support early development through commercialization. GMP conditions crucial. To this end, the purpose-built, 10,000-square-foot Bristol facility has five ISO-8 multifunctional cleanrooms, and two ISO-7 cleanrooms. These areas are dedicated to GMP small molecule manufacturing and product handling, meeting rigorous requirements for advanced cell therapy manufacturing. As such, with this facility Bio-Techne offers customers high-quality GMP materials backed by robust quality systems and reliable global supply. Pending Bio-Techne acquisition by Merck KGaA. The facility's opening comes amid Bio-Techne's pending acquisition by Merck KGaA, Darmstadt, Germany. That $11 billion deal was announced in June 2026. In September, Bio-Techne shareholders approved the transaction. It should be closing in late 2026 or early 2027. Why Bristol? But back to Bristol, Bio-Techne says it reflects a broader strategy to build a comprehensive manufacturing network in cell therapy. It joins recombinant protein manufacturing operations and other GMP capabilities in the company's home state of Minnesota. "Success increasingly depends on the ability to manufacture therapies consistently and at scale," Bio-Techne President and CEO Kim Kelderman said. "Our investment in Bristol demonstrates Bio-Techne's commitment to providing customers with [needed] GMP materials, manufacturing expertise, and supply chain reliability." The Bristol facility is now fully operational, manufacturing GMP-grade small molecules supporting global customers who are developing next-generation cell therapies. Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Bio-Techne Corporation, a Minneapolis-based life science company valued at $11.4 billion, has significantly outperformed the Nasdaq Composite in recent months. The stock gained 28.9% over the past three months, compared to the Nasdaq's 5.3% rise during the same period. Year-to-date, Bio-Techne shares climbed 23.3%, whilst advancing 37% over the past 52 years, surpassing the Nasdaq's YTD gains of 15.9% and annual returns of 19.3%. The company reported mixed financial results, with full-year sales remaining flat at $1.2 billion due to sluggish biotech funding and uneven biopharma demand. However, disciplined cost controls and operational efficiencies improved GAAP operating margins and net earnings. In its Q4 results announced in August, Bio-Techne met earnings expectations with adjusted EPS of $0.52, whilst revenue of $321.2 million exceeded Wall Street forecasts of $317.2 million.
Bio-Techne opens new Customer Experience Center in Düsseldorf to accelerate scientific discovery and customer collaboration. Sep 22, 2026, 09:00 ET * New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise * Regional hub will support researchers and organizations across the DACH and broader EMEA regions * Center strengthens collaboration, training and innovation within Europe's life sciences community MINNEAPOLIS and DÜSSELDORF, Germany, Sept. 22, 2026 /CNW/ - Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise. The new center serves as a regional hub where researchers, biopharmaceutical companies, biotechnology innovators and clinical laboratories can explore integrated technologies and workflows firsthand, helping accelerate scientific discovery, translational research and clinical impact. Located in one of Europe's leading centers for academic research and innovation, the Düsseldorf Customer Experience Center enables customers throughout the Germany, Austria, and Switzerland (DACH) region and the broader Europe, Middle East, and Africa (EMEA) region to engage directly with Bio-Techne scientists, technologies and solutions. The center has been designed to showcase integrated workflows in a single environment, giving researchers the opportunity to evaluate technologies, gain hands-on experience and identify approaches that can advance scientific discovery and improve patient outcomes. Through demonstrations and interactive learning experiences, visitors can explore techniques and applications across protein biology, spatial biology, cell therapy, molecular diagnostics, and analytical instrumentation. Beyond customer engagement, the Düsseldorf center will serve as a regional hub for learning, training, and collaboration. The facility will host workshops, thought leadership events and technical training programs while strengthening Bio-Techne's engagement with universities, research institutes and emerging biotechnology companies throughout the region. Professor Jörg Wischhusen, Ph.D. University Hospital Würzburg, scientific founder CatalYm and co-founder Toleris Biotherapeutics said, "Getting direct access to Bio-Techne's technologies, workflows and scientific experts in one location is an exciting prospect for researchers like us. The ability to evaluate technologies firsthand and experience complete workflows in action should help to make faster and more informed decisions that can accelerate research and development." "Researchers increasingly need partners who can help bridge discovery, translational research and clinical application," said Frank Splettstoesser, Experimental Anesthesiology AG Frede, University Hospital Bonn. "The Düsseldorf Customer Experience Center provides an environment where scientists can learn, collaborate, and explore innovative solutions that address complex biological questions. It demonstrates Bio-Techne's commitment to supporting scientific excellence across Europe." "The opening of our Düsseldorf Customer Experience Center represents a significant investment in the scientific community across Europe," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our goal is to provide researchers and clinicians with the tools, technologies and expertise they need to answer complex biological questions and improve human health. By creating a destination where scientists can experience innovative techniques firsthand, collaborate with our experts, and evaluate integrated workflows, we are helping accelerate breakthroughs from research to real-world impact." Düsseldorf Mayor Dr. Stephan Keller said, "Bio-Techne's investment in Düsseldorf reflects the strength of our region as a center for life science innovation and international business. We welcome the company's continued expansion and commitment to North Rhine-Westphalia and our city, further reinforcing our strong life sciences ecosystem and collaborative environment that benefits researchers, institutions and businesses alike." The new center also reflects Bio-Techne's commitment to sustainable growth and long-term investment in Europe. Located within a refurbished facility designed with modern energy-efficient features, the site provides convenient access for customers across Germany and the broader region while creating capacity for future expansion as customer needs evolve. By bringing together innovation, expertise and collaboration in a single location, the Düsseldorf Customer Experience Center reinforces Bio-Techne's commitment to empowering scientists with the tools and technologies needed to reach better answers and advance the future of life science research and healthcare. ABOUT BIO-TECHNE Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems(TM), Bio-Techne Spatial(TM), and Bio-Techne Diagnostics(TM), reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2026, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. MEDIA CONTACTS Investor Relations David Clair, Vice President [email protected] SOURCE Bio-Techne Corporation
Bio-Techne has achieved validation of its greenhouse gas reduction targets from the Science Based Targets initiative. The life sciences company aims to cut absolute Scope 1 and 2 emissions by 70% by fiscal 2031 from a fiscal 2025 baseline. In fiscal 2026, Bio-Techne reduced market-based Scope 1 and 2 emissions by 49% year-over-year. The company now sources 51% of its electricity from renewable sources after transitioning its Minneapolis headquarters and St Paul GMP facility to renewable power. Bio-Techne also committed that 81% of suppliers by spend will have science-based targets by fiscal 2030. The company completed its first comprehensive Scope 3 emissions inventory during the year. The Minnesota-based company generated over $1.2 billion in net sales in fiscal 2026.